AVITA MEDICAL, INC. Financials AVITA Medical, Inc. Australian S.E.
Equities
AVH
AU000000AVH4
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.62 AUD | -5.42% |
|
-6.43% | -38.93% |
| Apr. 17 | Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target is AU$3.03 | MT |
| Apr. 11 | BTIG Research Downgrades Avita Medical to Neutral From Buy | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,373 | 522.2 | 411.3 | 244.2 | 517.3 | 337.1 | - | - |
| Enterprise Value (EV) 1 | 1,373 | 423.1 | 259.8 | 127.5 | 442 | 317.3 | 335.2 | 344 |
| P/E ratio | -2,376 x | -8.44 x | -10.2 x | -6.15 x | -9.41 x | -6.23 x | -31.5 x | 26 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 80.7 x | 26.5 x | 10.2 x | 4.82 x | 6.75 x | 2.92 x | 2.06 x | 1.62 x |
| EV / Revenue | 80.7 x | 21.5 x | 6.45 x | 2.52 x | 5.77 x | 2.75 x | 2.05 x | 1.66 x |
| EV / EBITDA | -42.9 x | -11.9 x | -9.35 x | -3.33 x | -6.88 x | -5.59 x | -17.8 x | 38.8 x |
| EV / FCF | -46.9 x | -13.1 x | -7.03 x | -4.44 x | -7.34 x | -6.35 x | -19 x | 21.5 x |
| FCF Yield | -2.13% | -7.62% | -14.2% | -22.5% | -13.6% | -15.8% | -5.25% | 4.66% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 21,175 | 21,625 | 24,926 | 25,208 | 25,676 | 25,800 | - | - |
| Reference price 2 | 64.86 | 24.15 | 16.50 | 9.687 | 20.15 | 13.06 | 13.06 | 13.06 |
| Announcement Date | 8/29/19 | 8/27/20 | 8/26/21 | 2/23/23 | 2/22/24 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17.03 | 19.71 | 40.31 | 50.63 | 76.65 | 115.3 | 163.7 | 207.5 |
| EBITDA 1 | -32 | -35.56 | -27.8 | -38.31 | -64.24 | -56.73 | -18.81 | 8.861 |
| EBIT 1 | -34.75 | -58.99 | -36.6 | -40.46 | -65.2 | -57.29 | -18.47 | 9.151 |
| Operating Margin | -204.07% | -299.23% | -90.79% | -79.91% | -85.07% | -49.68% | -11.29% | 4.41% |
| Earnings before Tax (EBT) 1 | -34.78 | -58.09 | -36.6 | -39.17 | -53.98 | -54.85 | -13 | 15.89 |
| Net income 1 | -34.6 | -58.09 | -36.66 | -39.22 | -54.08 | -56.86 | -17.56 | 8.517 |
| Net margin | -203.24% | -294.68% | -90.94% | -77.47% | -70.56% | -49.31% | -10.73% | 4.11% |
| EPS 2 | -0.0273 | -2.861 | -1.613 | -1.574 | -2.140 | -2.098 | -0.4150 | 0.5017 |
| Free Cash Flow 1 | -29.28 | -32.26 | -36.95 | -28.75 | -60.21 | -49.99 | -17.61 | 16.02 |
| FCF margin | -171.97% | -163.62% | -91.66% | -56.77% | -78.56% | -43.34% | -10.76% | 7.72% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 180.8% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 188.09% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 8/29/19 | 8/27/20 | 8/26/21 | 2/23/23 | 2/22/24 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 10.2 | 13.53 | 10.72 | 11.35 | 14.21 | 10.98 | 11.71 | 13.82 | 13.91 | 15.76 | 17.92 | 21.25 | 21.7 | 17.14 | 25.42 | 32.76 | 38.77 | 31.41 |
| EBITDA 1 | -17.48 | -15.65 | -38.43 | -5.817 | -4.299 | -13.53 | -8.594 | -8.271 | -7.639 | -13.52 | -16.8 | -14.24 | -18.47 | -20.55 | -16.71 | -11.71 | -10.78 | -8.131 |
| EBIT 1 | -19.18 | -20.98 | -39.29 | -7.76 | -6.486 | -13.81 | -8.94 | -8.739 | -8.691 | -14.81 | -17.03 | -14.49 | -18.76 | -19.44 | -16 | -12.4 | -9.634 | -8.43 |
| Operating Margin | -187.97% | -155.07% | -366.64% | -68.35% | -45.65% | -125.84% | -76.33% | -63.22% | -62.49% | -93.94% | -95% | -68.2% | -86.46% | -113.38% | -62.94% | -37.84% | -24.85% | -26.84% |
| Earnings before Tax (EBT) 1 | -19.2 | - | -38.64 | -7.754 | -6.496 | -13.77 | -8.792 | -8.49 | -7.839 | -13.73 | -15.81 | -13.55 | -10.78 | -19.16 | -15.75 | -12.13 | -10.32 | -8.046 |
| Net income 1 | -20.4 | -31.31 | -38.65 | -7.767 | -6.506 | -13.78 | -8.798 | -8.496 | -7.874 | -13.77 | -15.83 | -13.57 | -10.8 | -19.17 | -15.76 | -12.13 | -10.33 | -8.059 |
| Net margin | -199.9% | -231.42% | -360.61% | -68.42% | -45.79% | -125.52% | -75.12% | -61.46% | -56.62% | -87.39% | -88.35% | -63.85% | -49.77% | -111.82% | -62% | -37.04% | -26.63% | -25.66% |
| EPS 2 | -0.0114 | - | -1.811 | -0.3368 | -0.2620 | -0.5533 | -0.3513 | -0.3345 | -0.3089 | -0.5527 | -0.6252 | -0.5295 | -0.4280 | -0.7284 | -0.5810 | -0.4488 | -0.3572 | -0.3065 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/29/19 | 1/31/20 | 8/27/20 | 5/13/21 | 8/26/21 | 5/12/22 | 8/11/22 | 11/10/22 | 2/23/23 | 5/11/23 | 8/10/23 | 11/9/23 | 2/22/24 | - | - | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | 6.91 |
| Net Cash position 1 | - | 99.1 | 151 | 117 | 75.3 | 19.8 | 1.85 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | 0.7797 x |
| Free Cash Flow 1 | -29.3 | -32.3 | -36.9 | -28.7 | -60.2 | -50 | -17.6 | 16 |
| ROE (net income / shareholders' equity) | -140% | -90.2% | -28.3% | -28.2% | -52.9% | -187% | -52% | 53.1% |
| ROA (Net income/ Total Assets) | - | -77.7% | -25.6% | -24.9% | -33.7% | -32.8% | -19.9% | 10.7% |
| Assets 1 | - | 74.81 | 143.4 | 157.6 | 160.4 | 173.3 | 88.29 | 79.74 |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | -1.580 | -1.120 | -2.290 | -1.530 | -0.7900 | - |
| Capex 1 | 1.47 | 0.82 | 1.23 | 0.66 | 2.11 | 1.61 | 1.82 | 2.15 |
| Capex / Sales | 8.66% | 4.14% | 3.06% | 1.31% | 2.75% | 1.4% | 1.11% | 1.04% |
| Announcement Date | 8/29/19 | 8/27/20 | 8/26/21 | 2/23/23 | 2/22/24 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.06
AUD
Average target price
39.74
AUD
Spread / Average Target
+204.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- RCEL Stock
- AVH Stock
- Financials AVITA Medical, Inc.
